Advertisement

Topics

ArQule, Inc. and Daiichi Sankyo Company, Limited Company Profile

18:07 EDT 23rd June 2018 | BioPortfolio

On December 19, 2008, ArQule and Daiichi Sankyo, Co., Ltd. signed a license, co-development and co-commercialization agreement to co-develop tivantinib in the U.S., Europe, South America and the rest of the world, excluding Japan, China (including Hong Kong), South Korea and Taiwan, where Kyowa Hakko Kirin Co., Ltd. has exclusive rights for development and commercialization.


News Articles [245 Associated News Articles listed on BioPortfolio]

Daiichi Sankyo to restructure vaccines subsidiary

Daiichi Sankyo is set to restructure its wholly-owned Kitasato Daiichi Sankyo Vaccine subsidiary into a specialised manufacturing division to enhance...Read More... The post Daiichi Sankyo to restruct...

Daiichi Sankyo Presents Phase 3 ENLIVEN Study of Pexidartinib, Demonstrating Statistically Significant Clinical Improvement Across Multiple Endpoints in Patients with Tenosynovial Giant Cell Tumor

Tokyo, Basking Ridge, NJ, and Munich – (June 4, 2018) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the phase 3 ENLIVEN study showed a statistically significan...

Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations (QuANTUM-R Study)

Tokyo, Munich, and Basking Ridge, NJ – (May 8, 2018) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announces that the pivotal QuANTUM-R phase 3 study of single agent quizartinib me...

Daiichi Sankyo to develop new inflammatory disease drugs

Daiichi Sankyo has formed a new consortium focused on research and discovery of medicines over a period of five years...Read More... The post Daiichi Sankyo to develop new inflammatory disease drugs a...

Daiichi Sankyo doses first patient in Phase ll trial of DS-8201

Daiichi Sankyo Company has dosed the first patient in a Phase ll trial evaluating the efficacy and safety of DS-8201...Read More... The post Daiichi Sankyo doses first patient in Phase ll trial of DS-...

BRIEF—Daiichi Sankyo US reorganization means 280 job cuts

Japanese pharma major Daiichi Sankyo says it will reorganize its US commercial organization as it continues…

Daiichi Sankyo’s Quizartinib Significantly Prolongs Overall Survival in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations

TOKYO, MUNICH, and BASKING RIDGE, N.J., May 8, 2018 /PRNewswire/ — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announces that the pivotal QuANTUM-R phase 3 study of single agent ...

Daiichi Sankyo reports on results for leukemia candidate

Daiichi Sankyo's quizartinib, a drug being tested in a Phase III trial as a treatment for patients with relapsed or refractor -More- 

Drugs and Medications [1311 Associated Drugs and Medications listed on BioPortfolio]

Benicar [Daiichi Sankyo, Inc]

These highlights do not include all the information needed to use Benicar safely and effectively. See full prescribing information for Benicar. Benicar (olmesartan medoxomil) tablets Initial U.S. Appr...

Evoxac capsules(cevimeline hydrochloride) [Daiichi Sankyo Pharma Development]

EVOXAC Capsules(cevimeline hydrochloride)

Ranitidine [WOCKHARDT LIMITED]

Ranitidine [WOCKHARDT LIMITED]

Drug Facts

Famotidine [WOCKHARDT LIMITED]

Famotidine Tablets, USP 20 mg

PubMed Articles [44 Associated PubMed Articles listed on BioPortfolio]

Characteristics of Occupational Injuries in a Pharmaceutical Company in Iran.

To prioritize occupational hazards in a Pharmaceutical Company in Iran using the analytical hierarchy process (AHP).

Assessment of medium-term cardiovascular disease risk after Japan's 2011 Fukushima Daiichi nuclear accident: a retrospective analysis.

To assess the medium-term indirect impact of the 2011 Fukushima Daiichi nuclear accident on cardiovascular disease (CVD) risks and to identify whether risk factors for CVD changed after the accident.

Roles of children and their parents in the reduction of radiation risk after the 2011 Fukushima Daiichi Nuclear Power Plant accident.

On March 11, 2011, Japan experienced its largest recorded earthquake with a magnitude of 9.0. The resulting tsunami caused massive damage to the Fukushima Daiichi Nuclear Power Plant reactors, and the...

Long-term outcomes of patients evacuated from hospitals near the Fukushima Daiichi nuclear power plant after the Great East Japan Earthquake.

After the accident of the Fukushima Daiichi nuclear power plant due to the Great East Japan Earthquake in March 2011, the Japanese government issued a mandatory evacuation order for people living with...

Radiocesium contamination in house dust within evacuation areas close to the Fukushima Daiichi nuclear power plant.

Outdoor decontamination efforts have been ongoing since the Fukushima Daiichi nuclear power plant (FDNPP) accident; however, little is known about indoor contamination. Therefore, house dust was sampl...

Clinical Trials [85 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Olmesartan Medoxomil Tablets 40 mg and Benicar® 40 mg Tablets of Daiichi Sankyo Inc., USA. Dosing periods of studies were ...

Comparative Study of Loxoprofen Sodium Transdermal Patch and Loxonin® Tablets for the Treatment of Acute Trauma

This study evaluates the non-inferiority of the new transdermal patch dosage form containing loxoprofen sodium (100 mg - Daiichi-Sankyo) in comparison with oral Loxonin® (60 mg tablet - D...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablet Under Fasting Conditions

Subjects to compare the single dose bioavailability of Torrent's Olmesartan Medoxomil Tablets 40 mg and Benicar 40 mg Tablets of Daichi Sankyo Inc. USA. Dosing periods of studies were sepa...

Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation (ETNA-AF-Hong Kong)

In order to understand the risks and benefits of edoxaban use in a real-world clinical setting in the NVAF indication, Daiichi-Sankyo Hong Kong proposed this non-interventional study (NIS)...

Edoxaban Treatment in Routine Clinical Practice for Patients With Non-Valvular Atrial Fibrillation (NVAF)

In order to understand the risks and benefits of edoxaban use in a real-world clinical setting in the NVAF indication, Daiichi-Sankyo Thailand proposed this non-interventional study (NIS) ...

Companies [1522 Associated Companies listed on BioPortfolio]

ArQule, Inc. and Daiichi Sankyo Company, Limited

On December 19, 2008, ArQule and Daiichi Sankyo, Co., Ltd. signed a license, co-development and co-commercialization agreement to co-develop tivantinib in the U.S., Europe, South ...

DAIICHI SANKYO EUROPE GmbH and SHARE

DAIICHI SANKYO is a global pharmaceutical company that focuses on researching and marketing innovative medications. The company was created in 2005 through the merger of two traditional Japanese e...

Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited, established in 2005 after the joint share transfer of two leading century-old Japanese pharmaceutical companies, is continuously generating innovative drugs that e...

Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. ...

ArQule Incorporated

ArQule has created a new technology platform for the discovery and production of novel chemical compounds with commercial potential. The Company has developed proprietary technologies for the identifi...

More Information about "ArQule, Inc. and Daiichi Sankyo Company, Limited" on BioPortfolio

We have published hundreds of ArQule, Inc. and Daiichi Sankyo Company, Limited news stories on BioPortfolio along with dozens of ArQule, Inc. and Daiichi Sankyo Company, Limited Clinical Trials and PubMed Articles about ArQule, Inc. and Daiichi Sankyo Company, Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ArQule, Inc. and Daiichi Sankyo Company, Limited Companies in our database. You can also find out about relevant ArQule, Inc. and Daiichi Sankyo Company, Limited Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...


Corporate Database Quicklinks



Searches Linking to this Company Record